A Randomized Controlled Trial with Bright Light and Melatonin for the Treatment of Delayed Sleep Phase Disorder: Effects on Subjective and Objective Sleepiness and Cognitive Function. (October 2013)

• Record Type: Journal Article
• Authors: Wilhelmsen-Langeland, Ane; Saxvig, Ingvild W.; Pallesen, Ståle; Nordhus, Inger-Hilde; Vedaa, Øystein; Lundervold, Astri J.; Bjorvatn, Bjørn
• Is Part Of: Journal of biological rhythms. Volume 28:Number 5(2013)
• Page Start: 306
• Page End: 321
• Publication Date: 2013-10
• Subjects: randomized controlled trial -- circadian rhythms -- delayed sleep phase disorder -- bright light -- melatonin -- treatment -- daytime function; Biological rhythms -- Periodicals; Circadian rhythms -- Periodicals; 571.77
• DOI: 10.1177/0748730413500126
• Languages: English
• ISSNs: 0748-7304

Abstract

Delayed sleep phase disorder (DSPD) is a circadian rhythm sleep disorder. Patients with DSPD have problems initiating sleep if they go to bed at a conventional time, and they often have problems waking at desired times. If they rise early in the morning, they usually experience severe sleepiness during morning hours. In the present study, we investigated the short- and long-term effects on measures of subjective and objective sleepiness and cognitive function of bright light and melatonin treatment alongside gradually advanced rise times in adolescents and young adults. Four treatment conditions were used in the short-term intervention (2 weeks): dim light (placebo) + placebo capsule, bright light + placebo capsule, dim light (placebo) + melatonin capsule, and bright light + melatonin capsule. This was followed by a long-term intervention (3 months) including 2 conditions: no treatment and combined bright light + melatonin treatment. Effects of treatment on sleepiness and fatigue were the primary outcome measures, and effects on cognitive function were secondary outcome measures. On a gradual advancement of the rise time schedule, all treatment conditions (bright light, melatonin, combination, and placebo) were almost equally effective in improving subjective daytime sleepiness, fatigue, and cognitive function in the 2-week study. The 2-week intervention showed no effect on objective sleepiness. Long-term treatment increased some of the positive effects seen after 2 weeks. The combined bright light and melatonin treatment improved subjective daytime sleepiness, fatigue, and cognitive function in the 3-month study. The no-treatment group returned to baseline values on most variables. In conclusion, a gradual advancement of rise times seems to produce positive effects on subjective sleepiness, fatigue, and cognitive performance during short-term treatment of patients with DSPD. However, the benefits from gradually advanced rise times seem to wear off, suggesting that the continuation of bright light and melatonin treatment is beneficial to maintain positive effects over time.